论文部分内容阅读
Compelling experimental and clinical evidence suggests that epidermal growthfactor receptor (EGFR) plays an important role in the pathogenesis of a variety ofhuman cancers;thus,providing a strong rationale for the development of receptorantagonists as effective and specific therapeutic strategies for the treatment ofEGFR-expressing cancers.Monoclonal antibodies (mAb),owing to their highspecificity towards a given target,represent a unique class of novel cancertherapeutics.A number of anti-EGFR mAb are currently being developed in ourclinic,including two that have been approved by the United States Food andDrug Administration for the treatment of refractory metastatic colorectal cancer(mCRC) and squamous cell carcinomas of the head and neck (SCCHN).Cetuximab(Erbitux,IMC-C225),an IgG1 mAb,has demonstrated significant antitumor activity,both as a single agent and in combination with chemotherapeutics and radiation,in patients with refractory mCRC and SCCHN,respectively.Panitumumab(Vectibix),an IgG2 mAb,has been approved as a single agent for the treatment ofpatients with refractory mCRC.These mAb,via blocking ligand/receptorinteractions,exert their biological activity via multiple mechanisms,includinginhibition of cell cycle progression,potentiation of cell apoptosis,inhibition ofDNA repair,inhibition of angiogenesis,tumor cell invasion and metastasis and,potentially,induction of immunological effector mechanisms.Anti-EGFR anti-bodies have demonstrated good safety profiles and potent anticancer activity inour clinic and may prove to be efficacious agents in the treatment of a variety ofhuman malignancies.
Compelling experimental and clinical evidence suggests that epidermal growthfactor receptor (EGFR) plays an important role in the pathogenesis of a variety of man cancers; thus, providing a strong rationale for the development of receptagonagonists as effective and specific therapeutic strategies for the treatment of EGFR-expressing cancers .Monoclonal antibodies (mAb), due to their high specificity for a given target, represent a unique class of novel cancertherapeutics. A number of anti-EGFR mAb are currently being developed in our bloodline, including two that have been approved by the United States Food and Drug Administration for the treatment of refractory metastatic colorectal cancer (mCRC) and squamous cell carcinomas of the head and neck (SCCHN) .Cetuximab (Erbitux, IMC-C225), an IgG1 mAb, has demonstrated significant antitumor activity, both as a single agent and in combination with chemotherapeutics and radiation, in patients with refractory mCRC and SCCHN, respectively. Panitumumab (Vectibi x), an IgG2 mAb, has been approved as a single agent for the treatment of patients with refractory mCRC.These mAb, via blocking ligand / receptorinteractions, exert their biological activity via multiple mechanisms, including inhibition of cell cycle progression, potentiation of cell apoptosis, inhibition of DNA repair, inhibition of angiogenesis, tumor cells invasion and metastasis and, potentially, induction of immunological effector mechanisms. Anti-EGFR anti-bodies have demonstrated good safety profiles and potent anticancer activity in clinic and may prove to be efficacious agents in the treatment of a variety ofhuman malignancies.